Shire (SHPG) Inactive 10-Q2005 Q2 Quarterly report

Filed: 5 Aug 05, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ABN, abnormal, absence, accuracy, acheived, activityNet, Additionally, aged, aided, alia, AMRO, annum, ascribe, binding, bridging, cent, Chancery, Chapter, characterization, check, chosen, Citicorp, comment, complementary, confirmed, contemplated, cure, DEA, denied, diverted, dividend, EBITDA, Employer, employment, emptive, English, entry, EQUETRO, ERISA, Error, facilityThe, filer, FOSRENOLFOSRENOL, freight, furniture, genetic, grace, greater, growthNote, handling, hearing, HSBC, Identification, idle, illegal, impracticable, incorporate, incurrence, INFORMATIONITEM, InformationThe, insolvency, inter, Irish, ix, law, LIBOR, LLC, low, mandatory, mark, Maurice, merging, misrepresentation, monthsto, MTSIn, multicurrency, NHS, niche, occurby, occurrence, ofacquiring, OtherOther, outThe, overdue, packaging, partnershipsThe, past, paymentof, percent, perfect, poll, pre, pretrial, principle, procurement, proxy, published, rare, ratio, refinancing, REMINYLDuring, repudiate, retrospective, revolving, rightsIn, Royal, scale, Scotland, Shiremet, shorter, sNDA, Sparta, spoilage, submissionpackage, surviving, thefourth, theproduct, thereunder, TKTShire, tosupport, undrawn, validly, vi, vii, viii, Washington, wasted, withdraw, withholding, withthe

Removed: assessment, Canadian, closing, covering, gained, good, guanfacine, human, leaving, medicinal, mg, nucleoside, NV, operation, Pharmaceutica, potential, reflect, reimburse, rest, restated, Rockville, standard

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SHPG similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

The certification set forth below is being submitted in connection with the Quarterly Report on Form 10-Q of Shire Pharmaceuticals Group plc for the quarter ended June 30, 2005 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

Matthew Emmens, the Chief Executive Officer and Angus Russell, the Chief Financial Officer of Shire Pharmaceuticals Group plc, each certifies that, to the best of his knowledge:

	1.	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

	2.	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Shire Pharmaceuticals Group plc.

Date: August 5, 2005

/s/ Matthew Emmens

Matthew Emmens

Chief Executive Officer

/s/ Angus Russell

Angus Russell

Chief Financial Officer